On December 9, 2020 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, reported the presentation of new preclinical data on its VISTA antagonist antibodies at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2020 (Press release, Kineta, DEC 9, 2020, View Source;utm_medium=rss&utm_campaign=kineta-presents-new-preclinical-data-at-esmo-virtual-congress-2020-on-its-vista-antagonist-antibodies [SID1234572510]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, presented the new preclinical data on the company’s fully human anti-VISTA antibodies in a virtual poster presentation on December 9th, 2020. Key findings from the presentation include the following:
VISTA is highly expressed on myeloid cells granulocytes, NK and NKT cells
VISTA is also expressed at moderate levels on Treg CD4 and CD8 T cells, while CD4/CD69 activated T cells are high expressers
VISTA binds to the 5 putative receptors already identified at either neutral or acidic pH
Kineta’s anti-VISTA antibodies selectively inhibit these interactions with different potencies
"The results presented at ESMO (Free ESMO Whitepaper) further validate VISTA as a novel innate immune target with the potential to reprogram the tumor microenvironment and improve survival for patients with cancer." said Thierry Guillaudeux. "Kineta’s anti-VISTA antibodies demonstrate exceptional selectivity and potency. We have several outstanding antibodies from which to choose a lead candidate and initiate IND enabling studies in early 2021."
VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated that anti-VISTA antibodies mediate tumor growth inhibition when administered alone and display additive efficacy in combination with PD-(L)1 and CTLA-4 targeted therapy.
Presentation Details:
Poster Title: Highly Potent Fully Human Anti-VISTA Antibodies Efficiently Abrogate the Interaction of VISTA to its Different Putative Receptors at Different pH
Date/Time: December 9, 2020 from 9:00 AM to 8:00 PM Central European Time
Presenter: Thierry Guillaudeux, PhD
Click on the link below to take you to the Kineta website where you can view the presentation:
VISTA Publications – Kineta VISTA Poster Presentation at ESMO (Free ESMO Whitepaper) Virtual Congress 2020